<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231630</url>
  </required_header>
  <id_info>
    <org_study_id>2019-11-0001</org_study_id>
    <nct_id>NCT04231630</nct_id>
  </id_info>
  <brief_title>Outpatient Exclusive Human Milk Diet for Single Infant With Complex Congenital Heart Disease</brief_title>
  <official_title>A Single Patient Observational Trial of an Exclusive Human Milk Diet to Provide and Evaluate Growth in a Single Infant at Home With Complex Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prolacta Bioscience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single patient observational trial to evaluate growth velocity and clinical outcomes of an&#xD;
      infant status post cardiac surgery who has failed to grow well and demonstrated intolerance&#xD;
      to cow milk-based and elemental formulas and fortifiers on a 100% human milk diet including a&#xD;
      human milk based human milk fortifier formulated for term infants fluid restricted due to&#xD;
      surgically correctable congenital conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single patient observational study to evaluate growth velocity and clinical outcomes of an&#xD;
      infant status post cardiac surgery who has failed to grow well and demonstrated intolerance&#xD;
      to cow milk-based and elemental formulas and fortifiers on a 100% human milk diet. Human milk&#xD;
      is defined as expressed human milk or donor milk and its derivatives, human milk-based&#xD;
      fortifier and human milk caloric fortifier.&#xD;
&#xD;
      The study hypothesis is that this infant if fed an exclusive human milk diet will have&#xD;
      improved growth in part due to data greater tolerability of the diet.&#xD;
&#xD;
      It is estimated that the study will require 90 days to complete. Growth in safety&#xD;
      observations will be collected only during the time the patient is receiving the diet.&#xD;
&#xD;
      The primary objective is to evaluate growth velocity (weight velocity [g/kg/day] of a single&#xD;
      infant receiving a 100% human milk diet including a human milk based human milk fortifier&#xD;
      formulated for term infants who are fluid restricted due to surgically correctable congenital&#xD;
      conditions. This will be compared to the infant's growth velocity prior to the initiation of&#xD;
      said diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth</measure>
    <time_frame>through study completion, approximately 6 months</time_frame>
    <description>Weight velocity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Linear growth</measure>
    <time_frame>through study completion, approximately 6 months</time_frame>
    <description>Length gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference growth</measure>
    <time_frame>through study completion, approximately 6 months</time_frame>
    <description>Head circumference growth</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Growth Delay</condition>
  <arm_group>
    <arm_group_label>Observational Case</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 infant will be enrolled as an observational case. Will receive an exclusive human milk diet at home.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolacta</intervention_name>
    <description>Will receive outpatient supplementation with donor human milk product added to mother's own milk</description>
    <arm_group_label>Observational Case</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Complex congenital heart disease in presence of poor linear and head circumference&#xD;
             growth and unable to tolerate cow's milk protein&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  n/a&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dell Medical School</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Steven Abrams</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 9, 2020</submitted>
    <returned>October 1, 2020</returned>
    <submitted>October 5, 2020</submitted>
    <returned>October 26, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

